658 related articles for article (PubMed ID: 14576477)
1. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus.
Phillips RW; Frierson HF; Moskaluk CA
Am J Surg Pathol; 2003 Nov; 27(11):1442-7. PubMed ID: 14576477
[TBL] [Abstract][Full Text] [Related]
2. CDX2, COX2 and MUC2 expressions in Barrett's esophagus: can they be useful in determination of the dysplasia?
Türkmen IÇ; Başsüllü N; Uraz S; Yerdel MA; Memışoğlu R; Bülbül Doğusoy G
Turk Patoloji Derg; 2012; 28(3):251-8. PubMed ID: 23011828
[TBL] [Abstract][Full Text] [Related]
3. Expression of CDX2 and MUC2 in Barrett's mucosa.
Steininger H; Pfofe DA; Müller H; Haag-Sunjic G; Fratianu V
Pathol Res Pract; 2005; 201(8-9):573-7. PubMed ID: 16259110
[TBL] [Abstract][Full Text] [Related]
4. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia.
Groisman GM; Amar M; Meir A
Mod Pathol; 2004 Oct; 17(10):1282-8. PubMed ID: 15167938
[TBL] [Abstract][Full Text] [Related]
5. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
6. Notch signaling pathway and Cdx2 expression in the development of Barrett's esophagus.
Tamagawa Y; Ishimura N; Uno G; Yuki T; Kazumori H; Ishihara S; Amano Y; Kinoshita Y
Lab Invest; 2012 Jun; 92(6):896-909. PubMed ID: 22449796
[TBL] [Abstract][Full Text] [Related]
7. Expression of resistin-like molecule beta in Barrett's esophagus: a novel biomarker for metaplastic epithelium.
Zheng L; Tong Q; Weng M; He J; Lv Q; Wu Z; Du Z; Mei H; Hou X
Dig Dis Sci; 2010 Jan; 55(1):32-9. PubMed ID: 19225886
[TBL] [Abstract][Full Text] [Related]
8. CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma.
Weimann A; Zimmermann M; Gross M; Slevogt H; Rieger A; Morawietz L
Int J Surg Pathol; 2010 Oct; 18(5):330-7. PubMed ID: 20444732
[TBL] [Abstract][Full Text] [Related]
9. Mucin histochemistry of intestinal metaplasia in Barrett's esophagus.
Jauregui HO; Davessar K; Hale JH; Kessimian N; Cenoz C
Mod Pathol; 1988 May; 1(3):188-92. PubMed ID: 3237699
[TBL] [Abstract][Full Text] [Related]
10. Esophageal adenocarcinoma arising in cervical inlet patch with synchronous Barrett's esophagus-related dysplasia.
Tanaka M; Ushiku T; Ikemura M; Shibahara J; Seto Y; Fukayama M
Pathol Int; 2014 Aug; 64(8):397-401. PubMed ID: 25143128
[TBL] [Abstract][Full Text] [Related]
11. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
[TBL] [Abstract][Full Text] [Related]
12. Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background.
Szachnowicz S; Cecconello I; Iriya K; Marson AG; Takeda FR; Gama-Rodrigues JJ
Clinics (Sao Paulo); 2005 Apr; 60(2):103-12. PubMed ID: 15880245
[TBL] [Abstract][Full Text] [Related]
13. Does CDX2 expression predict Barrett's metaplasia in oesophageal columnar epithelium without goblet cells?
Kerkhof M; Bax DA; Moons LM; van Vuuren AJ; van Dekken H; Steyerberg EW; Kuipers EJ; Kusters JG; Siersema PD;
Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1613-21. PubMed ID: 17206949
[TBL] [Abstract][Full Text] [Related]
14. Non-goblet cell population of Barrett's esophagus: an immunohistochemical demonstration of intestinal differentiation.
Chaves P; Cardoso P; de Almeida JC; Pereira AD; Leitao CN; Soares J
Hum Pathol; 1999 Nov; 30(11):1291-5. PubMed ID: 10571507
[TBL] [Abstract][Full Text] [Related]
15. Intestinal metaplasia in Barrett's oesophagus may be an epiphenomenon rather than a preneoplastic condition, and CDX2-positive cardiac-type epithelium is associated with minute Barrett's tumour.
Watanabe G; Ajioka Y; Takeuchi M; Annenkov A; Kato T; Watanabe K; Tani Y; Ikegami K; Yokota Y; Fukuda M
Histopathology; 2015 Jan; 66(2):201-14. PubMed ID: 25040564
[TBL] [Abstract][Full Text] [Related]
16. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
[TBL] [Abstract][Full Text] [Related]
17. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation.
Chinyama CN; Marshall RE; Owen WJ; Mason RC; Kothari D; Wilkinson ML; Sanderson JD
Histopathology; 1999 Dec; 35(6):517-24. PubMed ID: 10583575
[TBL] [Abstract][Full Text] [Related]
18. P63 Deficiency and CDX2 Overexpression Lead to Barrett's-Like Metaplasia in Mouse Esophageal Epithelium.
Fang Y; Li W; Chen X
Dig Dis Sci; 2021 Dec; 66(12):4263-4273. PubMed ID: 33469811
[TBL] [Abstract][Full Text] [Related]
19. CDX2 protein expression compared to alcian blue staining in the evaluation of esophageal intestinal metaplasia.
Johnson DR; Abdelbaqui M; Tahmasbi M; Mayer Z; Lee HW; Malafa MP; Coppola D
World J Gastroenterol; 2015 Mar; 21(9):2770-6. PubMed ID: 25759548
[TBL] [Abstract][Full Text] [Related]
20. Ectopic Cdx2 expression in murine esophagus models an intermediate stage in the emergence of Barrett's esophagus.
Kong J; Crissey MA; Funakoshi S; Kreindler JL; Lynch JP
PLoS One; 2011 Apr; 6(4):e18280. PubMed ID: 21494671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
